Skye Bioscience, Inc. SKYE 深 滬
等待開盤 10-28 09:30:00 美东时间
1.61
+0.070
+4.55%
華盛通- 最 高1.66
- 今 開1.58
- 成交量 53.26万股
- 最 低 1.57
- 昨 收 1.54
- 總市值 4989.13万
- 52周最高 5.96
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.14
- 委 比 -72.70%
- 總股本 3098.84万
- 歷史最高 17.6473
- 量 比 0.78
- 振 幅 5.84%
- 歷史最低 1.14
- 每 手 1
- 風險率 1.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gain...
10-07 01:09
US Stocks Mixed; Dow Falls 100 Points
U.S. stocks traded mixed this morning, with the Dow Jones index falling more th...
10-06 23:05
Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
Skye Bioscience announced topline results from its Phase 2a CBeyond™ study of nimacimab, a CB1 inhibitor. Nimacimab monotherapy did not meet its primary weight loss endpoint, likely due to suboptimal drug exposure. However, when combined with semaglutide, nimacimab demonstrated clinically meaningful additional weight loss compared to semaglutide alone. The combination showed a favorable safety profile with no increase in gastrointestinal or neuro...
10-06 11:00
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
HC Wainwright & Co. Initiates Coverage On Skye Bioscience with Buy Rating, Announces Price Target of $20
HC Wainwright & Co. analyst Ananda Ghosh initiates coverage on Skye Bioscience (NASDAQ:SKYE) with a Buy rating and announces Price Target of $20.
09-30 19:22
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of their outstanding shares is at $165.6 million.
09-27 05:06
Could This New Drug Be The Safer Way To Fight Obesity?
Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies.
09-20 02:19
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
Skye Bioscience announced Phase 1b results for nimacimab, showing safety, tolerability, and no neuropsychiatric adverse events in metabolic-associated steatotic liver disease (MASLD) patients. Gastrointestinal side effects were mild, supporting its potential in treating metabolic diseases. Key findings include predictable pharmacokinetics, low immunogenicity, and no serious adverse events or discontinuations. Nimacimab's differentiated tolerabili...
09-19 11:00
Skye's Nimacimab Boosts Tirzepatide Results And Helps Maintain Weight Loss In Mouse Studies
Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today reported results from two new
09-04 19:10
Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
Skye Bioscience reported promising preclinical data for nimacimab, a peripheral CB1-inhibiting antibody, showing over 40% weight loss when combined with tirzepatide, superior post-treatment weight maintenance vs monlunabant, and reduced rebound weight gain. Nimacimab is positioned as a potential standalone, combination, and maintenance therapy for obesity, with Phase 2 results expected in late 2025.
09-04 11:00
